研究单位:[1]Gilead Sciences[2]Arcus Biosciences, Inc.[3]Siteman Cancer Center,Saint Louis,Missouri,United States,63110[4]Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research,Nashville,Tennessee,United States,37203[5]The University of Texas, MD Anderson Cancer Center,Houston,Texas,United States,77030[6]Monash Health,Clayton,Victoria,Australia,3168[7]Alfred Health,Melbourne,Victoria,Australia,3004[8]ICON Cancer Center,Kurralta Park,Australia,5037[9]Westmead Hospital,Sydney,Australia,2145[10]Sichuan Cancer Hospital,Chengdu,China,610040[11]Zhejiang Cancer Hospital,Hangzhou,China,310005[12]Guangxi Medical University Cancer Hospital,Nanning,China,530012[13]Shanghai East Hospital,Shanghai,China,200120[14]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China,430030[15]CHU de Bordeaux,Pessac,France,33604[16]Fondazione IRCCS Istituto Nazionale dei Tumori,Milano,Italy,20133[17]Istituto Nazionale Tumori Fondazione G. Pascale,Napoli,Italy,80131[18]Sarawak General Hospital,Sarawak,Malaysia,93586[19]Hospital Universitario Virgen del Rocio,Sevilla,Spain,41013[20]Kaohsiung Medical University Chung-Ho Memorial Hospital,Kaohsiung City,Taiwan,80756[21]Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital,Kaohsiung,Taiwan,833[22]China Medical University Hospital,Taichung,Taiwan,40402[23]National Taiwan University Hospital,Taipei City,Taiwan,100229[24]Taipei Veterans General Hospital,Taipei City,Taiwan,11217[25]Chang Gung Memorial Hospital, Linkou,Taoyuan,Taiwan,33308[26]Barts Health NHS Foundation Trust,London,United Kingdom,EC1A 7BE
研究目的:
Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies.